Guggenheim Reiterates Buy Rating for Benitec Biopharma (NASDAQ:BNTC)

Guggenheim reissued their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) in a research note published on Tuesday morning,Benzinga reports. The firm currently has a $17.00 target price on the biotechnology company’s stock. A number of other brokerages have also weighed in on BNTC. Oppenheimer began coverage on Benitec Biopharma in a […]

Leave a Reply

Your email address will not be published.

Previous post Credo Technology Group (NASDAQ:CRDO) Given New $70.00 Price Target at Needham & Company LLC
Next post Workday (NASDAQ:WDAY) Lowered to “Hold” Rating by StockNews.com